Last reviewed · How we verify
Intravenous saline 0.9%
Intravenous saline 0.9% restores fluid and electrolyte balance by delivering isotonic sodium chloride solution directly into the bloodstream.
Intravenous saline 0.9%, marketed by the University of Nottingham, is a well-established product in the healthcare sector. The key composition patent is set to expire in 2028, providing a period of exclusive protection. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | Intravenous saline 0.9% |
|---|---|
| Sponsor | University of Nottingham |
| Drug class | Crystalloid fluid / Electrolyte replacement |
| Modality | Small molecule |
| Therapeutic area | Fluid and electrolyte management / Critical care |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% NaCl) is an isotonic crystalloid fluid that matches the osmolarity of blood plasma, allowing safe expansion of intravascular volume without causing cellular water shifts. It replaces lost fluids and electrolytes in dehydration, hemorrhage, and perioperative settings, and serves as a vehicle for medication delivery.
Approved indications
- Hypovolemia and dehydration
- Perioperative fluid replacement
- Maintenance of vascular access and medication delivery
- Hemorrhagic shock (initial resuscitation)
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypernatremia
- Phlebitis at infusion site
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (PHASE3)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Tocilizumab in Lung Transplantation (PHASE2)
- Improving Preterm Kidney Outcomes With Caffeine (PHASE2)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous saline 0.9% CI brief — competitive landscape report
- Intravenous saline 0.9% updates RSS · CI watch RSS
- University of Nottingham portfolio CI